Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao(Stanford Medicine), Ash A. Alizadeh(Stanford University), Chad Tang(Stanford University), June H. Myklebust(Oslo University Hospital), Bindu Varghese(Stanford University), Saar Gill(Stanford University), Max Jan(Stanford University), Adriel C. Cha(Stanford University), Charles K. F. Chan(Stanford University), Brent Tan(Palo Alto University), Christopher Y. Park(Palo Alto University), Feifei Zhao(Stanford University), Holbrook E. Kohrt(Stanford University), Raquel Malumbres(University of Miami), Javier Briones(Universitat Autònoma de Barcelona), Randy D. Gascoyne(BC Cancer Agency), Izidore S. Lossos(University of Miami), Ronald Levy(Stanford University), Irving L. Weissman(Palo Alto University), Ravindra Majeti(Stanford University)
Cited by 1,075Open Access
Abstract
Related Papers
Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
D G Altman, Berthold Lausen, Willi Sauerbrei et al.|JNCI Journal of the National Cancer Institute|1994|1.1k